Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT05575323 Recruiting - Spinal Metastases Clinical Trials

Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases

BLEND
Start date: October 15, 2022
Phase: N/A
Study type: Interventional

The BLEND RCT aims to evaluate the (cost-)effectiveness of same-day SBRT and surgical stabilization with or without decompression for the treatment of symptomatic, unstable spinal metastases on physical functioning four weeks after the start of treatment, compared with the standard of care (surgery followed by radiotherapy as soon as the wound healed sufficiently).

NCT ID: NCT05573893 Recruiting - Breast Cancer Clinical Trials

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

PROVIDENCE
Start date: September 12, 2023
Phase:
Study type: Observational

This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with documented Human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic breast cancer (BC) and in patients with documented HER2-low unresectable or metastatic BC receiving T-DXd in line with the applicable summary of product characteristics (SmPC) within routine clinical practice in Germany. In addition, patients will be informed about use of digital healthcare application (DiGA).

NCT ID: NCT05573815 Recruiting - Brain Metastases Clinical Trials

Evaluation of Clinical Decision Support System for Brain Metastasis Using Brain MR Images

Start date: September 16, 2022
Phase: N/A
Study type: Interventional

BT-M01 is a software that has been pre-learned based on a brain metastasis detection model using brain MR images, and clinical decision support system for brain metastasis by automatically analyzing brain MR images by assisting the medical team. The specific aims of this study are to evaluate efficacy of BT-M01 for brain metastasis compared to the sensitivity and false positive rates of radiologists group.

NCT ID: NCT05566743 Recruiting - Cancer of Pancreas Clinical Trials

A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas

Start date: September 11, 2022
Phase: Phase 2
Study type: Interventional

A randomized phase II study evaluating maintenance therapy after first line induction chemotherapy in metastatic cancer pancreas.

NCT ID: NCT05566574 Recruiting - Solid Tumor Clinical Trials

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Start date: September 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.

NCT ID: NCT05564949 Recruiting - Cancer Clinical Trials

A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases

Start date: September 20, 2022
Phase: N/A
Study type: Interventional

The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.

NCT ID: NCT05559853 Recruiting - Brain Metastases Clinical Trials

Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

Start date: September 22, 2022
Phase:
Study type: Observational

The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).

NCT ID: NCT05557045 Recruiting - Solid Tumor Clinical Trials

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Start date: October 10, 2022
Phase: Phase 1
Study type: Interventional

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.

NCT ID: NCT05554302 Recruiting - Brain Metastases Clinical Trials

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

CONCORDANT
Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.

NCT ID: NCT05553522 Recruiting - Brain Metastases Clinical Trials

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Start date: January 29, 2024
Phase: Phase 1
Study type: Interventional

This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab. The combined use of SRS with the three drugs is considered investigational.